US008669290B2
`
`(12) United States Patent
`US 8,669,290 B2
`(10) Patent No.:
`Sawa et al.
`(45) Date of Patent:
`*Mar. 11, 2014
`
`(54) AQUEOUS LIQUID PREPARATION
`CONTAINING
`
`2-AMINO-3-(4-BROMOBENZOYL)
`PHENYLACETIC ACID
`
`(71) Applicant: Senju Pharmaceutical Co., Ltd., Osaka
`(JP)
`
`Inventors:
`
`(72)
`
`Shirou Sawa, Hyogo (JP); Shuhei
`Fuj ita, Hyogo (JP)
`
`(73) Assignee: Senju Pharmaceutical Co., Ltd., Osaka
`(JP)
`
`(*)
`
`Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`
`This patent is subject to a terminal dis-
`claimer.
`
`(21)
`
`Appl. No.: 13/687,242
`
`(22)
`
`Filed:
`
`Nov. 28, 2012
`
`(65)
`
`Prior Publication Data
`
`US 2013/0090384 A1
`
`Apr. 11, 2013
`
`8/1999 Sawa
`5,942,508 A
`12/1999 Hellberg et a1.
`5,998,465 A
`6,162,393 A * 12/2000 De Bruiju et a1.
`6,274,592 B1
`8/2001 Sawa
`6,274,609 B1
`8/2001 Yasueda et a1.
`6,319,513 B1
`11/2001 Dobrozsi
`6,369,112 B1
`4/2002 Xia
`6,383,471 B1
`5/2002 Chen et a1.
`6,395,746 B1
`5/2002 Cagle et a1.
`2001/0056098 A1
`12/2001 Sawa
`2007/0082857 A1
`4/2007 Sawa
`
`.............. 422/28
`
`FOREIGN PATENT DOCUMENTS
`
`AU
`CA
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`WO
`WO
`WO
`W0
`WO
`
`707 119
`2 013188
`62-126124
`1-104023
`02083323
`2-124819
`5-223052
`9-503791
`11-228404
`2002-308764
`96/14829
`00/59475
`01/15677
`W0 0115677 A2 *
`02/13804
`
`9/1995
`9/1990
`6/1987
`4/1989
`3/1990
`5/1990
`8/1993
`4/1997
`8/1999
`10/2002
`5/1996
`10/2000
`3/2001
`3/2001
`2/2002
`
`Related US. Application Data
`
`OTHER PUBLICATIONS
`
`(62)
`
`Division of application No. 13/353,653, filed on Jan.
`19, 2012, now Pat. No. 8,497,304, which is a division
`ofapplication No. 10/525,006, filed as application No.
`PCT/JP2004/000350 on Jan. 16, 2004, now Pat. No.
`8,129,431.
`
`(30)
`
`Foreign Application Priority Data
`
`New Drugs in Japan, 2001, 2001 Edition, Published byYakuji Nippo
`Ltd., May 11, 2001, pp. 27-29, and its English translation of the
`material portions.
`
`(Continued)
`
`Jan. 21, 2003
`
`(JP) ................................. 2003-012427
`
`Primary Examiner 7 Layla Soroush
`
`(51)
`
`(52)
`
`(58)
`
`(56)
`
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`
`Int. Cl.
`A01N 37/18
`A61K 31/165
`A01N 37/44
`A61K 31/24
`A01N 37/10
`A61K 31/19
`US. Cl.
`USPC ............ 514/619; 514/535; 514/570; 514/618
`Field of Classification Search
`USPC .......................................... 514/619, 535, 570
`See application file for complete search history.
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`4,045,576
`4,683,242
`4,910,225
`5,110,493
`5,475,034
`5,540,930
`5,558,876
`5,597,560
`5,603,929
`5,653,972
`
`*
`
`*
`
`>>>>>>>>>>
`
`8/1977
`7/1987
`3/1990
`5/1992
`12/1995
`7/1996
`9/1996
`1/1997
`2/1997
`8/1997
`
`Welstead, Jr. et a1.
`Poser
`................. 514/561
`Ogawa et a1.
`Cherng-Chyi et a1.
`Yanni et a1.
`Guy
`................... 424/427
`Desai et a1.
`Bergamini et a1.
`Desai et a1.
`Desai et a1.
`
`Page 1 of 10
`
`(74) Attorney, Agent, or Firm 7 Wenderoth, Lind & Ponack,
`L.L.P.
`
`(57)
`
`ABSTRACT
`
`An aqueous liquid preparation of the present invention con-
`taining 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its
`pharmacologically acceptable salt or a hydrate thereof, an
`alkyl aryl polyether alcohol type polymer such as tyloxapol,
`or a polyethylene glycol fatty acid ester such as polyethylene
`glycol monostearate is stable. Since even in the case where a
`preservative is incorporated into said aqueous liquid prepa-
`ration,
`the preservative exhibits a sufiicient preservative
`effect for a long time, said aqueous liquid preparation in the
`form of an eye drop is useful for the treatment of blepharitis,
`conjunctivitis, scleritis, and postoperative inflammation.
`Also, the aqueous liquid preparation of the present invention
`in the form of a nasal drop is useful for the treatment of
`allergic rhinitis and inflammatory rhinitis (e.g. chronic rhini-
`tis, hypertrophic rhinitis, nasal polyp, etc.).
`
`30 Claims, No Drawings
`
`LUPIN EX 1001
`
`LUPIN EX 1001
`
`Page 1 of 10
`
`

`

`US 8,669,290 B2
`Page 2
`
`(56)
`
`References Cited
`
`OTHER PUBLICATIONS
`
`ISTA Pharmaceuticals, “New Drug Applications: Xibrom”,http://
`www.drugs.com/nda/xibrom,040525.htrnt, accessed online Sep.
`19, 2007.
`Nolan et al., “The Topical Anti-Inflammatory and Analgesic Proper-
`ties of Bromfenic in Rodents”, Agents and Actions, vol. 25, No. 1-2,
`pp. 77-85, Aug. 1988.
`Corrected partial English translation of New Drugs in Japan, 2001,
`2001 Edition, Published by Yakuji Nippo Ltd., May 11, 2001, pp.
`27-29, previously submitted on Apr. 11, 2005.
`
`Complete English translation of New Drugs in Japan, 2001, 2001
`Edition, Published byYakuji Nippo Ltd., May 11, 2001, pp. 27-29.
`Notice of Opposition dated Feb. 19, 2009 issued by EPO in connec-
`tion with the corresponding European patent application and Oppo-
`sition.
`http://medical-dictionary.thefreedictionary.com/prolohylactic
`accessed Dec. 15, 2009.
`H. Scott et al., “Comparing the Surface Chemical Properties and the
`Effect of Salts on the Cloud Point of a Conventional Nonionic
`Surfactant, Octoxynol 9 (Triton X-100), and of its Oligomer,
`Tyloxapol (Triton WR-l339)”, Journal of Colloid and Interface Sci-
`ence, vol. 205, pp. 496-502, 1998.
`
`* cited by examiner
`
`Page 2 of 10
`
`Page 2 of 10
`
`

`

`1
`AQUEOUS LIQUID PREPARATION
`CONTAINING
`
`2-AMINO-3-(4-BROMOBENZOYL)
`PHENYLACETIC ACID
`
`This is a divisional of Ser. No. 13/353,653 filed Jan. 19,
`2012, which is a divisional of Ser. No. 10/525,006, filed Mar.
`28, 2005, now issued as US. Pat. No. 8,129,431, which is a
`US. national stage of International Application No. PCT/
`JP2004/000350 filed Jan. 16, 2004.
`
`TECHNICAL FIELD
`
`The present invention relates to an aqueous liquid prepa-
`ration containing 2-amino-3-(4-bromobenzoyl)phenylacetic
`acid or a pharmacologically acceptable salt thereof or a
`hydrate thereof. More particularly,
`the present
`invention
`relates to an aqueous liquid preparation containing 2-amino-
`3-(4-bromobenzoyl)phenylacetic acid or a pharmacologi-
`cally acceptable salt thereof or a hydrate thereof and an alkyl
`aryl polyether alcohol type polymer or a polyethylene glycol
`fatty acid ester.
`
`BACKGROUND ART
`
`Benzoylphenylacetic acid derivatives including bromfenac
`(generic name) of formula (I):
`
`o
`
`NH2
`
`0 0 COOH
`
`Br
`
`of which chemical name is 2-amino-3-(4-bromobenzoyl)
`phenylacetic acid are known as disclosed in JP-A-23052/
`1977 and its corresponding US. Pat. No. 4,045,576.
`2-Amino-3-(4-bromobenzoyl)phenylacetic acid, its pharma-
`cologically acceptable salt and a hydrate thereofare known as
`a non-steroidal anti-inflammatory agent, and they are effec-
`tive against inflammatory diseases of anterior or posterior
`segment of the eye, such as blepharitis, conjunctivitis, scleri-
`tis, and postoperative inflammation in the field of ophthal-
`mology, and its sodium salt has been practically used in the
`form of eye drops (“New Drugs in Japan, 2001”, 2001 Edi-
`tion, Published by Yakuji Nippo Ltd., May 11, 2001, p.
`27-29).
`The eye drop as mentioned above is designed to stabilize
`2-amino-3-(4-bromobenzoyl)phenylacetic acid by means of
`addition of a water-soluble polymer (e.g. polyvinylpyrroli-
`done, polyvinyl alcohol, etc.) and a sulfite (e.g. sodium
`sulfite, potassium sulfite, etc.) (Japanese patent No. 2,683,
`676 and its corresponding US. Pat. No. 4,910,225).
`In addition, as an eye drop other than the above-mentioned
`one, Japanese patent No. 2,954,356 (corresponding to US.
`Pat. Nos. 5,603,929 and 5,653,972) discloses a stable oph-
`thalmic composition which comprises incorporating an anti-
`bacterial quaternary ammonium polymer and boric acid into
`an acidic ophthalmic agent. The acidic agent described
`therein includes, for example, 2-amino-3-(4-bromobenzoyl)
`phenylacetic acid.
`Further, in Japanese patent No. 2,954,356, there is the
`following description-“Benzalkonium chloride is a widely
`used preservative in ophthalmic solutions. However, benza-
`lkonium chloride and other quaternary ammonium com-
`
`Page 3 of 10
`
`US 8,669,290 B2
`
`2
`
`pounds are generally considered to be incompatible with
`ophthalmic compositions ofdrugs with acidic groups, such as
`nonsteroidal anti-inflammatory drugs. These preservatives
`lose their ability to function as they form complexes with the
`charged drug compounds”.
`In these prior art references, there is no disclosure that alkyl
`aryl polyether alcohol type polymers or polyethylene glycol
`fatty acid esters are able to stabilize an aqueous liquid prepa-
`ration of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or
`its pharmacologically acceptable salt, and inhibit decrease in
`preservative effect of benzalkonium chloride and other qua-
`ternary ammonium compounds.
`
`DISCLOSURE OF THE INVENTION
`
`It is an object of the present invention to provide an aque-
`ous liquid preparation comprising 2-amino-3-(4-bromoben-
`zoyl)phenylacetic acid or a pharmacologically acceptable salt
`thereof or a hydrate thereof, which is stable within a pH range
`giving no irritation to eyes and in which, when a preservative
`such as benzalkonium chloride is incorporated therein, pre-
`servative effect of the preservative does not substantially
`deteriorate.
`
`Another object of the invention is to provide a method for
`stabilizing an aqueous liquid preparation of 2-amino-3-(4-
`bromobenzoyl)phenylacetic acid or a pharmacologically
`acceptable salt thereof or a hydrate thereof.
`Further object of the invention is to provide an aqueous
`liquid preparation comprising 2-amino-3-(4-bromobenzoyl)
`phenylacetic acid or a pharmacologically acceptable salt
`thereof or a hydrate thereofand a preservative, wherein, when
`specifically a quaternary ammonium salt such as benzalko-
`nium chloride is incorporated as a preservative, decrease in
`preservative effect of said preservative is inhibited.
`As a result of various studies, the inventors of the present
`invention have found that, by adding, for example, an alkyl
`aryl polyether alcohol type polymer such as tyloxapol, or a
`polyethylene glycol fatty acid ester such as polyethylene
`glycol monostearate to an aqueous liquid preparation of
`2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharma-
`cologically acceptable salt thereof or a hydrate thereof, the
`aqueous solution becomes stable within a pH range giving no
`irritation to eyes, and change ofthe 2-amino-3-(4-bromoben-
`zoyl)phenylacetic acid over time can be inhibited, and fur-
`thermore, when the aqueous solution contains a preservative,
`deterioration in the preservative effect of said preservative
`can be inhibited for a long period oftime. The inventors ofthe
`present invention have further studied extensively and com-
`pleted the present invention.
`Namely, the present invention relates to:
`(1) An aqueous liquid preparation comprising 2-amino-3-(4-
`bromobenzoyl)phenylacetic acid or a pharmacologically
`acceptable salt thereof or a hydrate thereof, and an alkyl aryl
`polyether alcohol type polymer or a polyethylene glycol fatty
`acid ester,
`(2) The aqueous liquid preparation according to the above (1),
`wherein the alkyl aryl polyether alcohol type polymer has a
`polymerization degree of 3 to 10, the alkyl contains 1 to 18
`carbon atoms, the aryl is a phenyl residue, and the polyether
`alcohol is represented by the formula O(CH2CH20)XH in
`which X is an integer of 5 to 100,
`(3) The aqueous liquid preparation according to the above (1)
`or (2), wherein the alkyl aryl polyether alcohol type polymer
`is tyloxapol,
`(4) The aqueous liquid preparation according to the above (1),
`wherein the carbon number of the fatty acid in the polyethyl-
`ene glycol fatty acid ester is 12 to 18,
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`Page 3 of 10
`
`

`

`US 8,669,290 B2
`
`3
`(5) The aqueous liquid preparation according to the above (1)
`or (4), wherein the polyethylene glycol fatty acid ester is
`polyethylene glycol monostearate,
`(6) The aqueous liquid preparation according to any one of
`the above (1) to (3), wherein the concentration of the alkyl
`aryl polyether alcohol type polymer is selected from a range
`of minimum concentration of 0.01 w/v % to maximum con-
`centration of 0.5 w/v %,
`(7) The aqueous liquid preparation according to any one of
`the above (1), (2) or (4), wherein the concentration of the
`polyethylene glycol fatty acid ester is selected from a range of
`minimum concentration of 0.02 w/v % to maximum concen-
`tration of 0.1 w/v %,
`(8) The aqueous liquid preparation according to any one of
`the above (1)
`to (7), wherein the concentration of the
`2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharma-
`cologically acceptable salt thereof or a hydrate thereof is 0.01
`to 0.5 w/v %,
`(9) The aqueous liquid preparation according to any one of
`the above (1) to (8), wherein benzalkonium chloride is con-
`tained as a preservative,
`(10) The aqueous liquid preparation according to anyone of
`the above (1) to (9), wherein the pharmacologically accept-
`able salt of 2-amino-3-(4-bromobenzoyl)phenylacetic acid is
`a sodium salt,
`(11) The aqueous liquid preparation according to any one of
`the above (1) to (10), wherein the pH of the aqueous liquid
`preparation is within a range of 7 to 9,
`(12) The aqueous liquid preparation according to the above
`(11), wherein the pH of the aqueous liquid preparation is
`within a range of 7.5 to 8.5,
`(13) The aqueous liquid preparation according to any one of
`the above (1) to (12), wherein the aqueous liquid preparation
`is an eye drop,
`(14) The aqueous liquid preparation according to any one of
`the above (1) to (12), wherein the aqueous liquid preparation
`is a nasal drop,
`(15) An eye drop comprising sodium 2-amino-3-(4-bro-
`mobenzoyl)phenylacetate hydrate and 0.01 to 0.5 w/v % of
`tyloxapol,
`(16) An eye drop comprising sodium 2-amino-3-(4-bro-
`mobenzoyl)phenylacetate hydrate and 0.02 to 0.1 w/v % of
`polyethylene glycol monostearate,
`(17) A method for stabilizing 2-amino-3-(4-bromobenzoyl)
`phenylacetic acid or a pharmacologically acceptable salt
`thereof or a hydrate thereof in an aqueous liquid preparation,
`which comprises incorporating tyloxapol or polyethylene
`glycol monostearate into an aqueous liquid preparation con-
`taining 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a
`pharmacologically acceptable salt
`thereof or a hydrate
`thereof, and
`(18) A method for inhibiting decrease in preservative effect of
`a preservative in an aqueous liquid preparation of 2-amino-
`3-(4-bromobenzoyl)phenylacetic acid or a pharmacologi-
`cally acceptable salt thereof or a hydrate thereof, which com-
`prises
`incorporating tyloxapol or polyethylene glycol
`monostearate into an aqueous liquid preparation containing
`2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharma-
`cologically acceptable salt thereof or a hydrate thereof and a
`preservative.
`According to the present invention, a stable aqueous liquid
`preparation containing 2-amino-3-(4-bromobenzoyl)pheny-
`lacetic acid or a pharmacologically acceptable salt thereof or
`a hydrate thereof can be prepared by incorporating an alkyl
`aryl polyether alcohol type polymer such as tyloxapol, or a
`polyethylene glycol fatty acid ester such as polyethylene
`glycol monostearate into an aqueous liquid preparation con-
`
`5
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`4
`
`taining 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a
`pharmacologically acceptable salt
`thereof or a hydrate
`thereof. Also, an aqueous liquid preparation of the present
`invention, wherein a preservative is incorporated, has a suf-
`ficient preservative effect.
`
`Therefore, the aqueous liquid preparation of the present
`invention is advantageously used as an eye drop for the treat-
`ment of, for example, blepharitis, conjunctivitis, scleritis, and
`postoperative inflammation. In addition, such aqueous liquid
`preparation can be used as a nasal drop for the treatment of,
`for example, allergic rhinitis and inflammatory rhinitis (e.g.
`chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
`
`The pharmacologically acceptable salt of 2-amino-3-(4-
`bromobenzoyl)phenylacetic acid includes, for example, an
`alkali metal salt such as sodium salt and potassium salt, and
`an alkaline earth metal salt such as calcium salt and magne-
`sium salt, among which sodium salt is especially preferable.
`
`2-Amino-3-(4-bromobenzoyl)phenylacetic acid and its
`pharmacologically acceptable salt can be prepared according
`to the method as described in JP-A-23052/1977 (correspond-
`ing to US. Pat. No. 4,045,576) or by a similar method thereof.
`These compounds can be obtained as their hydrate depending
`on synthetic conditions and recrystallization conditions. The
`hydrate includes 1/2 hydrate,
`1 hydrate, and 3/2 hydrate,
`among which 3/2 hydrate is preferable.
`
`In the aqueous liquid preparation of the present invention,
`the content
`(concentration range) of 2-amino-3-(4-bro-
`mobenzoyl)phenylacetic acid or a pharmacologically accept-
`able salt thereof or a hydrate thereof is usually about 0.01 to
`0.5 w/v %, preferably about 0.05 to 0.2 w/v %, especially
`about 0.1 w/v %, and it is preferable to appropriately vary the
`content depending on the purpose of use and the degree of
`disease to be treated.
`
`The carbon number of the alkyl in the an alkyl aryl poly-
`ether alcohol type polymer which is a non-ionic surfactant
`used as a stabilizer for 2-amino-3-(4-bromobenzoyl)pheny-
`lacetic acid or a pharmacologically acceptable salt thereof or
`a hydrate thereof is approximately 1 to 18. Specifically, the
`alkyl group includes, for example, methyl, ethyl, propyl, iso-
`propyl, cyclopropyl, butyl,
`isobutyl, sec-butyl,
`tert-butyl,
`cyclobutyl, pentyl, isopentyl, neopentyl, tert-pentyl, 1-ethyl-
`propyl, 4-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbu-
`tyl, 1,2-dimethylbutyl, 2-ethylbutyl, cyclopentyl, hexyl,
`cyclohexyl, heptyl,
`isoheptyl,
`octyl,
`isooctyl, nonyl,
`isononyl, decyl, isodecyl, undecyl, isoundecyl, dodecyl, isod-
`odecyl, tridecyl, isotridecyl, tetradecyl, isotetradecyl, penta-
`decyl, isopentadecyl, hexadecyl, isohexadecyl, heptadecyl,
`isoheptadecyl, octadecyl, isooctadecyl, and isomers thereof,
`among which octyl and its isomer (e.g. isooctyl, sec-octyl,
`1-methylheptyl, 1-ethylhexyl, 2-ethylhexyl, 1-propylpentyl,
`1,5-dimethylhexyl, 1,1,3,3-tetramethylbutyl, etc.) are prefer-
`able, and 1,1,3,3-tetramethylbutyl which is an isomer of octyl
`groups is especially preferable.
`
`The aryl in the alkyl aryl polyether alcohol type polymer
`can be preferably a phenyl residue. The polyether alcohol can
`be represented by the formula O(CH2CH20)XH in which X is
`an integer of 5 to 100, preferably 5 to 30, more preferably 8 to
`10. The average polymerization degree is preferably about 3
`to 10.
`
`Among the above-mentioned alkyl aryl polyether alcohol
`type polymers, tyloxapol having the following formula is
`especially preferable.
`
`Page 4 of 10
`
`Page 4 of 10
`
`

`

`US 8,669,290 B2
`
` C(CH3)3
`
`R: (CHZCHZO) xH
`x : 8-10
`m < 6
`
`The fatty acid of the polyethylene glycol fatty acid ester
`which is a non-ionic surfactant used as a stabilizer for
`
`2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharma-
`cologically acceptable salt thereof or a hydrate thereof can be
`preferably a fatty acid having the carbon number of 12 to 18.
`Specific examples of such polyethylene glycol fatty acid
`esters are polyethylene glycol monostearate (e.g. polyoxyl 8
`stearate, polyoxyl 40 stearate, etc.), polyethylene glycol
`monolaurate, polyethylene glycol monooleate, polyethylene
`glycol diisostearate, polyethylene glycol dilaurate, polyeth-
`ylene glycol dioleate, and the like. Among these compounds,
`polyethylene glycol monostearate is preferable, and polyoxyl
`40 stearate is especially preferable. The polyoxyl 40 stearate
`is a monostearic acid ester of an ethylene oxide condensed
`polymer, and can be represented by the formula C17H35COO
`(CH2CH20)nH which is a non-ionic surfactant and n is about
`40.
`
`Although the content (concentration range) of the alkyl
`aryl polyether alcohol type polymer in the aqueous liquid
`preparation of the present invention depends on the kind of
`compounds used, the minimum concentration is about 0.01
`w/v % and the maximum concentration is about 0.5 w/v %.
`
`With respect to the tyloxapol content (concentration range),
`for example, the minimum content is about 0.01 w/v %, 0.02
`w/v % or 0.03 w/v %, and the mamximum content is about
`0.05 w/v %, 0.1 w/v %, 0.3 w/v % or 0.5% w/v, and preferably
`the minimum content is about 0.02 w/v % and the maximum
`content is about 0.05 w/v %.
`
`Although the content (concentration range) of the polyeth-
`ylene glycol fatty acid ester in the aqueous liquid preparation
`of the present invention depends on the kind of compounds
`used, it is within a range of about 0.02 w/v % of minimum
`concentration to about 0.1 w/v % ofmaximum concentration.
`
`For example, the content (concentration range) of polyethyl-
`ene glycol monostearate is within a range ofabout 0.02 w/v %
`ofminimum content to about 0.1 w/v % ofmaximum content,
`and preferably within a range of about 0.02 w/v % of the
`minimum content to about 0.05 w/v % of the maximum
`content.
`
`The incorporation ratio of tyloxapol in the aqueous liquid
`preparation ofthe invention is within a range ofthe minimum
`content of about 0.1 or 0.2 part by weight to the maximum
`content ofabout 0.5, 1, 3 or 5 parts by weight, relative to 1 part
`by weight of 2-amino-3-(4-bromobenzoyl)phenylacetic acid
`or its pharmacologically acceptable salt or a hydrate thereof.
`The incorporation ratio of polyethylene glycol monostear-
`ate in the aqueous liquid preparation of the present invention
`is within a range ofthe minimum content of about 0.2 part by
`weight to the maximum content of about 0.5 or 1 part by
`weight, relative to 1 part by weight of 2-amino-3-(4-bro-
`
`Page 5 of 10
`
`6
`acid or
`mobenzoyl)phenylacetic
`acceptable salt or a hydrate thereof.
`
`its pharmacologically
`
`The preservative used in the present invention includes, for
`example, quaternary ammonium salts (e.g. benzalkonium
`chloride, benzethonium chloride, etc.), chlorhexidine glu-
`conate, and the like, among which benzalkonium chloride is
`especially preferable.
`
`Further, so long as the purpose of the present invention is
`achieved, conventional various additives such as isotonics,
`buffers, thickners, stabilizers, chelating agents, pH control-
`ling agents, perfumes and the like may be appropriately added
`to the aqueous liquid preparation ofthe present invention. The
`isotonics include sodium chloride, potassium chloride, glyc-
`erine, mannitol, sorbitol, boric acid, glucose, propylene gly-
`col and the like. The buffers include, for example, phosphate
`buffer, borate buffer, citrate buffer, tartarate buffer, acetate
`buffer, boric acid, borax, amino acids, and the like. The thick-
`ners include polyvinylpyrrolidone, carboxymethylcellulose,
`carboxypropylcellulose,
`hydroxyethylcellulose,
`hydrox-
`ypropylcellulose, hydroxypropylmethylcellulose, polyvinyl
`alcohol, sodium polyacrylate, and the like. The stabilizers
`include sulfites such as sodium sulfite and the like. The chelat-
`
`ing agents include sodium edetate, sodium citrate, condensed
`sodium phosphate and the like. The pH controlling agents
`include hydrochloric acid, sodium hydroxide, phosphoric
`acid, acetic acid and the like. The perfumes include 1-men-
`thol, borneol, camphor, Eucalyptus oil, and the like.
`
`With respect to the concentrations of the above various
`additives in the aqueous liquid preparation of the present
`invention,
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`the isotonic is incorporated into an osmotic pressure ratio of
`about 0.8 to 1.2, and the concentrations of the buffer and the
`thickner to be added are about 0.01 to 2 w/v % and 0.1 to 10
`
`w/v %, respectively.
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`The pH of the aqueous liquid preparation of the present
`invention is adjusted to about 6 to 9, preferably about 7 to 9,
`especially about 7.5 to 8.5.
`
`So long as the purpose of the present invention is achieved,
`other same or different kind of active ingredients may be
`appropriately added.
`
`The aqueous liquid preparation ofthe present invention can
`be prepared by per se known method or according to the
`method as described in the Japanese Pharmacopoeia, 14th
`Edition, General Rules for Preparations, Solutions or Oph-
`thalmic solutions.
`
`The aqueous liquid preparation ofthe present invention can
`be applied to warm-blooded animals such as human, rat,
`mouse, rabbit, cow, pig, dog, cat, and the like.
`The aqueous liquid preparation ofthe present invention can
`be prepared easily by dissolving the above-mentioned com-
`ponents in, for example, distilled water or sterile purified
`water. For example, the aqueous liquid preparation in the
`form of an eye drop can be used for the treatment of inflam-
`matory diseases in anterior or posterior segment of the eye
`such as blepharitis, conjunctivitis, scleritis, postoperative
`inflammation, and the like. The dose of the aqueous liquid
`preparation containing 0.1 w/v % of sodium 2-amino-3-(4-
`bromobenzoyl)phenylacetate hydrate is, for example, admin-
`istered to an adult 3 to 6 times daily in an amount of 1 to 2
`drops per one time. Depending on the degree of diseases,
`frequency of dosing is appropriately controlled.
`
`Page 5 of 10
`
`

`

`7
`BEST MODE FOR CARRYING OUT THE
`INVENTION
`
`8
`0.02 w/v % of tyloxapol is more stable than that in composi-
`tion A-02 containing 0.15 w/v % of tyloxapol.
`
`US 8,669,290 B2
`
`The present invention is illustrated by way ofthe following
`Experimental Examples and Working Examples, but it is not
`restricted by these Examples.
`
`5
`
`Experimental Example 2
`
`Experimental Example 1
`
`Stability Test of Sodium
`2-amino-3-(4-bromobenzoyl)phenylacetate
`
`Stability Test of Sodium
`2-amino-3-(4-bromobenzoyl)phenylacetate
`
`10
`
`Four eye drops of sodium 2-amino-3-(4-bromobenzoyl)
`phenylacetate comprising the components as shown in Table
`1 were prepared, filled respectively into a polypropylene con-
`tainer and subjected to stability test at 60° C.
`
`Five eye drops of sodium 2-amino-3-(4-bromobenzoyl)
`phenylacetate comprising the components as shown in Table
`2 were prepared, filled respectively into apolypropylene con-
`tainer and preserved at 60° C. for 4 weeks, and then the
`content of 2-amino-3-(4-bromobenzoyl)phenylacetic acid
`and the pH in each eye drop were measured.
`TABLE 2
`
`Components
`
`A-04
`
`A-05
`
`A-06
`
`A-07
`
`A-08
`
`0.1 g
`
`Sodium 2-amino-3-(4—
`bromobenzoyl)phenyl-
`acetate
`1.1 g
`Boric acid
`1.1 g
`Borax
`Benzalkonium chloride 0.005 g
`Polysorbate 80
`7
`Tyloxapol
`0.02 g
`Polyoxyl 40 stearate 7
`Polyvinyl-
`pyrrolidone (K-30)
`Sodium edetate
`Sodium hydroxide
`Sterile purified
`water
`Total volume
`pH
`60° C.,
`4 weeks
`
`2.0 g
`
`0.02 g
`q.s.
`q.s.
`100 mL
`8.17
`Remaining 92.6
`rate (%)
`pH
`
`8.15
`
`0.1g
`
`0.1 g
`
`0.1 g
`
`0.1 g
`
`1.1 g
`1.1 g
`0.005 g
`7
`0.05 g
`7
`
`2.0 g
`
`0.02 g
`q.s.
`q.s.
`100 mL
`8.16
`90.9
`
`1.1 g
`1.1 g
`1.1 g
`1.1 g
`0.005 g
`0.005 g
`i
`7
`0.03 g 7
`7
`0.02 g
`2.0 g
`
`2.0 g
`
`0.02 g
`q.s.
`q.s.
`100 mL
`8.15
`92.0
`
`0.02 g
`q.s.
`q.s.
`100 mL
`8.19
`93.4
`
`1.1 g
`1.1 g
`0.005 g
`i
`7
`0.05 g
`1.0 g
`
`0.02 g
`q.s.
`q.s.
`100 mL
`8.19
`93.1
`
`8.16
`
`8.15
`
`8.13
`
`8.14
`
`TABLE 1
`
`Component
`
`compmson
`Example 1
`
`A-01
`
`A-02
`
`A-03
`
`0.1 g
`
`Sodium 2-amino-3-(4—
`bromObenzoyl)
`pheliylafietate
`1.5 g
`Bone ac1d
`Benzalkonium chloride 0.005 g
`Polysorbate 80
`0.15 g
`P01y0Xy140 stCarate *
`er1e UII C W3. CI
`.S.
`331°21‘31” ,fi d
`t
`i
`Total vglume
`q 100 mL
`pH
`7.0
`Remaining rate (%) at
`51.3
`60° C- afier 4 weeks
`
`0.1 g
`
`0.1 g
`
`0.1 g
`
`1.5 g
`1.5 g
`1.5 g
`0.005 g
`0.005 g
`0.005 g
`7
`7
`7
`i
`0-15 g i
`.S
`.S.
`.S.
`0'02 g
`i
`0'15 g
`q 100 mL q 100 mL q 100 mL
`7.0
`7.0
`7.0
`63.7
`73.8
`89.6
`
`Table 2 shows the remaining rate and the pH of sodium
`40 2-amino-3-(4-bromobenzoyl)phenylacetate after storage at
`60° C. for 4 weeks, when the remaining rate of sodium
`.
`.
`2-am1no-3-(4-bromobenzoyl)phenylacetate at
`the time of
`production of eye drops is set to 100%. The remaining rate is
`a value obtained by correcting moisture vaporization from the
`45 container. As is apparent from Table 2, the remaining rate of
`.
`.
`.
`SOdlum.2911111103'(4'bromObenZ0y1)Pheny1acetate 11} The
`compos1tions A-04, A-05, A-06, A-07 and A-08 conta1mng
`0.02 w/v %, 0.03 w/v % and 0.05 w/v % oftyloxapol or 0.02
`.
`.
`.
`50 w/v % and 0.05 w/v % ofpolyoxyl 40 stearate is not less than
`90% after storage at 60° C. fon4 weeks, wh1ch 1nd1cates that
`those compos1tions have sufiic1ent stab111ty for eye drops.
`
`Experimental Example 3
`
`.
`.
`.
`.
`.
`indicates
`The remaimng rate (%) 1n the above Table 1
`.
`.
`.
`.
`.
`values obtained by correct1ng m01sture vapor1zation from the
`.
`.
`.
`.
`conta1ner. As 1s apparent from the Table 1, stability test was
`.
`.
`.
`0
`carried out under the cond1tions Of pH 7'0 at 60 C' for 4 60
`weeks, and sodium 2-am1no-3-(4-bromobenzoyl)phenylac-
`.
`.
`etate in each eye drop was stable 1n the order of tyloxapol-
`containin
`re aration> 01 ox 1 40 stearate containin
`t' g >p 1p
`b t 50 y ty'
`.
`t'
`prepara ion p0 ysor a e
`£011 a1n1ng prepara 1on.
`Further, Wlth respect to eye drops comalnlng tYIOXZIPOI
`(compositions A-02 and A-03), sodium 2-amino-3-(4-bro-
`mobenzoyl)phenylacetate in composition A-03 containing
`
`55
`
`P
`
`ueous
`1
`es 0
`reserva 1ve
`ec
`L‘
`fA
`tT t
`t' Eff
`.
`q
`.
`.
`.
`Preparat1on Conta1mng Sodium
`.
`2-am1no-3-(4-bromobenzoyl)phenylacetate
`
`111
`’d
`
`q
`
`g
`
`Preservative effect test of compositions A-04, A-05 and
`.
`.
`.
`A-07 of Exper1mental Example 2 was carned out against
`.
`Staphylococcus aureus (here1nafter referred to as S. aureus),
`Escherichia Cali
`(hereinafter
`referred to as E.
`coli),
`Pseudomonas aeruginosa (hereinafter referred to as P.
`65 aeruginosa), Candida albicans (hereinafter referred to as C.
`albicans) and Aspergillus niger (hereinafter referred to as A.
`niger).
`
`Page 6 of 10
`
`Page 6 of 10
`
`

`

`9
`The results are shown in Tables 3-1, 3-2 and 3-3.
`
`10
`
`US 8,669,290 B2
`
`TABLE 3-1
`
`Cell count CFU/mL
`
`A-04
`
`S. aureus
`E. 0021'
`P. aeruginasa
`C. albicans
`A. niger
`
`Inoculum
`count
`
`2.1 x 106
`6.5 x 106
`5.8 x 106
`3.2 x 105
`1.8 x 105
`
`6 hours
`after
`inoculation
`
`24 hours
`after
`inoculation
`
`7 days
`after
`inoculation
`
`14 days
`after
`inoculation
`
`21 days
`after
`inoculation
`
`28 days
`after
`inoculation
`
`3.0 ><10l
`0
`0
`i
`i
`
`0
`0
`0
`i
`i
`
`0
`0
`0
`0
`0
`
`0
`0
`0
`0
`0
`
`0
`0
`0
`0
`0
`
`0
`0
`0
`0
`0
`
`TABLE 3-2
`
`Cell count CFU/mL
`
`A-05
`
`S. aureus
`E. 0021'
`P. aeruginasa
`C. albicans
`A. niger
`
`Inoculum
`count
`
`2.1x106
`6.5 x 106
`5.8 x 106
`3.2 x 105
`1.8 x 105
`
`6 hours
`after
`inoculation
`
`24 hours
`after
`inoculation
`
`7 days
`after
`inoculation
`
`14 days
`after
`inoculation
`
`21 days
`after
`inoculation
`
`28 days
`after
`inoculation
`
`l.7><105
`0
`0
`i
`i
`
`2.0><10l
`0
`0
`i
`i
`
`0
`0
`0
`0
`0
`
`0
`0
`0
`0
`0
`
`0
`0
`0
`0
`0
`
`0
`0
`0
`0
`0
`
`TABLE 3-3
`
`
`Cell count CFU/mL
`
`A-07
`
`Inoculum
`count
`
`6 hours
`after
`inoculation
`
`24 hours
`after
`inoculation
`
`7 days
`after
`inoculation
`
`14 days
`after
`inoculation
`
`21 days
`after
`inoculation
`
`28 days
`after
`inoculation
`
`0
`0
`0
`0
`0
`3.1 x 104
`2.7 ><106
`S. aureus
`0
`0
`0
`0
`0
`0
`7.4 x 106
`E. 0021'
`0
`0
`0
`0
`0
`0
`8.8 x 106
`P. aeruginasa
`0
`0
`0
`0
`i
`i
`4.6 x 105
`C. albicans
`
`A. niger 0 1.0 x 105 i i 0 0 0
`
`
`
`
`
`
`
`As is apparent from Tables 3-1, 3-2 and 3-3, the preserva- 45
`tive effect of composition A-04 was found to be compatible
`with EP-criteria A in European Pharmacopoeia (EP), and
`those of compositions A-05 and A-07 were found to be com-
`patible with EP-criteria B.
`
`50
`
`The EP-criteria A and EP-criteria B are given in the fol-
`lowing.
`EP-Criteria A:
`
`V1able cell counts of bacteria (S. aureus, P aeruginosa) 6
`hours, 24 hours, and 28 days after inoculation decrease to not
`more than 1/ 100, not more than 1/ 1000, and undetectable,
`respectively.
`
`V1able cell count of fungi (C. albicans, A. niger) 7 hours
`after inoculation decreases to not more than 1/100, and there-
`after, the cell count levels off or decreases.
`EP-Criteria B
`
`V1able cell counts of bacteria (S. aureus, P. aeruginosa) 24
`hours and 7 days after inoculation decrease to not more than
`1/ 10 and not more than 1/ 1000, respectively, and thereafter,
`the cell count levels off or decreases.
`
`55
`
`60
`
`65
`
`Page 7 of 10
`
`Viable cell count of fungi (C. albicans, A. niger) 14 days
`after inoculation decreases to not more than 1/ 10, and there-
`after, the cell count keeps the same level as that of 14 days
`after inoculation.
`
`Example 1
`
`Eye Drop
`
`Sodium 2-arnino-3-(4-
`bromobenzoyl)phenylacetate 3/2 hydrate
`Boric acid
`Borax
`Benzalkonium chloride
`Tyloxapol
`Polyvinylpyrrolidone (K-30)
`Sodium edetate
`Sodium hydroxide
`Sterile purified water
`
`0.1 g
`
`1.1 g
`1.1 g
`0.005 g
`0.02 g
`2.0 g
`0.02 g
`q.s.
`to make total volume
`of 100 mL
`pH 8.17
`
`Page 7 of 10
`
`

`

`US 8,669,290 B2
`
`An eye drop is prepared using the above components in a
`conventional manner.
`
`11
`
`Example 2
`
`Eye Drop
`
`Sodium 2-amino-3-(4—
`bromobenzoyl)phenylacetate 3/2 hydrate
`Boric acid
`Borax
`Benzalkonium chloride
`Tyloxapol
`Polyvinylpyrrolidone (K-30)
`Sodium edetate
`Sodium hydroxide
`Sterile purified water
`
`0.1 g
`
`1.1 g
`1.1 g
`0.005 g
`0.05 g
`2.0 g
`0.02 g
`q.s.
`to make total volume
`of 100 mL
`pH 8.16
`
`An eye drop is prepared using the above components in a
`conventional manner.
`
`Example 3
`
`Eye Drop
`
`Sodium 2-amino-3-(4—
`bromobenzoyl)phenylacetate 3/2 hydrate
`Boric acid
`Borax
`Benzalkonium chloride
`Polyoxyl 40 stearate
`Polyvinylpyrrolidone (K-30)
`Sodium edetate
`Sodium hydroxide
`Sterile purified water
`
`0.1 g
`
`1.1 g
`1.1 g
`0.005 g
`0.02 g
`2.0 g
`0.02 g
`q